MedTrace Logo

The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07467564 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2026-05-14

No results posted yet for this study

Summary

This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.

Conditions

Interventions

DRUG

Dupilumab

This study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice.

Sponsors & Collaborators

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-24
Primary Completion
2027-05-24
Completion
2027-05-24
FDA Drug
Yes

Countries

  • Saudi Arabia
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07467564 on ClinicalTrials.gov